Cite
HARVARD Citation
Petrylak, D. et al. (n.d.). 922TiPEV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). Annals of oncology. p. . [Online].